Skip to main content

Table 2 Clinicopathologic factors related to chronic lymphocytic thyroiditis in 172 patients with PTC

From: Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis

 

CLT(-)

CLT(+)

Χ2/t-test

P-value

Count

%

Count

%

Gender

 Female

107

(13.7)

45

(6.3)

1.874

0.171

 Male

17

(86.3)

3

(93.8)

  

Age (Mean ±S.D)

50.06±11.51

 

46.44±10.62

 

1.893

0.060

 < 45

39

(31.5)

21

(43.8)

2.304

0.129

 ≥ 45

85

(68.5)

27

(56.3)

  

Tumor Size(mm)(Mean ±S.D)

0.92 ±0.73

 

0.88±0.69

 

0.383

0.702

 < 1.0 cm

90

(72.6)

34

(70.8)

0.908

0.635

 ≥ 1.0 cm

34

(27.4)

14

(29.2)

  

Multifocality

 Absent

94

(75.8)

35

(72.9)

0.154

0.695

 Present

30

(24.2)

13

(27.1)

  

Bilaterality

 Absent

101

(81.5)

38

(79.2)

0.117

0.733

 Present

23

(18.5)

10

(20.8)

  

Extrathyroidal extension

 Absent

76

(61.3)

34

(70.8)

1.367

0.242

 Present

48

(38.7)

14

(29.2)

  

Central LM metastasis

 Absent

66

(53.2)

32

(66.7)

2.550

0.110

 Present

58

(46.8)

16

(33.3)

  

Lateral LM metastasis

 Absent

110

(88.7)

44

(91.7)

0.323

0.570

 Present

14

(11.3)

4

(8.3)

  

TNM stage

 I & II

71

(57.3)

36

(75.0)

5.770

0.056

 III

40

(32.3)

11

(22.9)

  

 IVa

13

(10.5)

1

(2.1)

  

BRAF mutation

 Negative

22

(17.7)

20

(41.7)

10.732

0.001

 Positive

102

(82.3)

28

(58.3)

  
  1. LN Lymph node, TNM Tumor/node/metastasis